Home » Stocks » Intersect ENT

Intersect ENT, Inc. (XENT)

Stock Price: $20.49 USD -0.90 (-4.21%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 670.07M
Revenue (ttm) 85.42M
Net Income (ttm) -61.46M
Shares Out 32.70M
EPS (ttm) -1.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $20.49
Previous Close $21.39
Change ($) -0.90
Change (%) -4.21%
Day's Open 21.50
Day's Range 20.35 - 21.69
Day's Volume 638,181
52-Week Range 5.97 - 31.46

More Stats

Market Cap 670.07M
Enterprise Value 607.75M
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 32.70M
Float 29.16M
EPS (basic) -1.91
EPS (diluted) -1.92
FCF / Share -1.05
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.38M
Short Ratio 2.34
Short % of Float 4.32%
Beta 1.29
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 7.84
PB Ratio 7.28
Revenue 85.42M
Operating Income -60.93M
Net Income -61.46M
Free Cash Flow -34.05M
Net Cash 62.31M
Net Cash / Share 1.91
Gross Margin 102.29%
Operating Margin -71.34%
Profit Margin -72.00%
FCF Margin -39.86%
ROA -21.97%
ROE -59.33%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 3
Overweight 0
Hold 6
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

(-0.34% downside)
Current: $20.49
Target: 20.42
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth0.62%12.64%22.35%27.79%59.62%115.2%205.83%-
Gross Profit87.3785.8680.8065.7149.3128.369.782.03
Operating Income-45.39-25.01-17.60-26.11-26.94-18.08-17.97-16.49
Net Income-42.99-22.92-16.36-25.22-26.63-18.36-18.37-16.37
Shares Outstanding31.3930.3129.1228.4226.1611.381.461.00
Earnings Per Share-1.37-0.76-0.56-0.89-1.02-1.61-12.57-16.38
Operating Cash Flow-27.25-13.84-8.04-20.06-20.09-17.95-19.10-16.15
Capital Expenditures-3.73-2.12-2.28-2.07-1.52-0.37-0.47-1.41
Free Cash Flow-30.98-15.96-10.32-22.13-21.61-18.32-19.57-17.56
Cash & Equivalents90.6410110210412448.4412.292.12
Total Debt10.89-----1.452.00
Net Cash / Debt79.7510110210412448.4410.840.12
Book Value11812111711413053.81-76.62-58.72
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Intersect ENT, Inc.
Country United States
Employees 402
CEO Thomas A. West

Stock Information

Ticker Symbol XENT
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Unique Identifier NASDAQ: XENT
IPO Date July 24, 2014


Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.